- INOVIQ (IIQ) teams up with Promega to co-market its EXO-NET exosome capture technology and Promega’s Nucleic Acid purification systems worldwide
- IIQ CEO Dr Leearne Hinch says Promega “is the ideal partner to expand the global reach of INOVIQ’s EXO-NET exosome capture technology”
- The agreement runs for three years with optional extension periods
- Promega has well-established customer bases including doctors’ offices, laboratory researchers, government health agencies, and related parties
- INOVIQ shares are up 4.88 per cent to 86 cents at 2:08 pm AEST
INOVIQ (IIQ) has teamed up with Promega to co-market its EXO-NET exosome capture technology and Promega’s Nucleic Acid purification systems worldwide.
INOVIQ specialises in offering exosome capture technology which ultimately provides a sample of cells from a patient believed to be presenting with possible cancers.
“Promega is the ideal partner to expand the global reach of INOVIQ’s EXO-NET exosome capture technology,” IIQ CEO Dr Leearne Hinch said.
The agreement will run for three years with optional extension periods.
INOVIQ is now confident it can move ahead marketing its cancer detection technology to the world and Promega will assist in this given that it already has access to well-established customer bases including doctors’ offices, laboratory researchers, government health agencies, and related parties.
INOVIQ shares are up 4.88 per cent to 86 cents at 2:08 pm AEST.